1 mL BAC
9 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 1 mL
SingleApproved OtherMixedModerate confidenceSourced
Thymosin alpha-1
An immune-modulating peptide used in some jurisdictions and studied across highly varied infections, liver disease and immune conditions.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
Two community-provenance subcutaneous lines from an authenticated research forum - a daily microdose near 450 mcg and a 1.5 mg every-third-day pulse. Community reports only, not a validated or clinician-directed schedule.
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.
Reported quantities by phase
Select a point for its calculation examples- Daily microdose450 mcgReports cluster at 400-500 mcg daily and are often run 20 days on, 10 days off; duration is not standardised.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 450 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw27 U
20-30 U reference band
2 mL BAC
18 units
resulting U-100 draw
- Concentration
- 2.5 mg/mL
- BAC added
- 2 mL
3 mL BAC
27 units
resulting U-100 draw
- Concentration
- 1.667 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Human StudySubcutaneousTwice weekly
Adults in historical chronic hepatitis studies
1.6 mg subcutaneously twice weekly in several disease-specific programmes
The review found mixed hepatitis results and does not support transferring this schedule across indications.
View sourceHuman StudySubcutaneousDaily loading then twice weekly
Five adults with common variable immune deficiency and depression
1.6 mg subcutaneously daily for one week, then twice weekly for seven weeks
This was a very small open-label proof-of-concept study, not confirmatory evidence.
View sourceCommunity GuideSubcutaneous in reportsTwice weekly or daily in differing reports
online research community summary and immune-stack reports
The spotlight repeats 1.6 mg subcutaneously twice weekly; community immune blends also use 500 mcg TA-1 plus 300 mcg thymulin daily with short higher-dose periods
Blend compositions and seasonal or vaccine-adjunct schedules conflict within the channel and are not quality-controlled clinical protocols; raw/peptide-education/pe-thymosin-alpha1.md:18-25 and 58-69.
View sourceCommunity GuideSubcutaneous in reportsDaily microdose or every-third-day pulse in differing reports
authenticated research-forum (Peppys) immune-support reports
Subcutaneous daily microdosing clusters around 400-500 mcg (a reference chart lists 450 mcg daily), frequently run 20 days on and 10 days off; a separate clinician-derived pulse of 1.5 mg every third day is raised toward 3 mg daily at the onset of a cold, and an immune-stack maintenance figure near 500 mcg daily also appears
Forum provenance from an authenticated archive with usernames omitted. Reported quantities and cadences conflict, the archive frames all use as research-subject use, and a widely repeated short-shelf-life claim is described there as a debunked myth. Routes are kept as subcutaneous, with a separate nasal-spray form noted independently.
View sourceEvidence summary
An immune-modulating peptide used in some jurisdictions and studied across highly varied infections, liver disease and immune conditions.
Protocol basis
The page reports common disease-specific research schedules while emphasising that regulatory status and evidence vary by jurisdiction and indication.
Community provenance (Peppys)
An authenticated research-forum archive records two recurring subcutaneous patterns: a daily microdose in the region of 400-500 mcg, frequently cycled 20 days on and 10 days off, and a clinician-derived pulse of roughly 1.5 mg every third day that some raise toward 3 mg daily at the onset of a cold. An immune-stack maintenance figure near 500 mcg daily also appears. The archive notes that thymosin alpha-1 is authorised as Zadaxin in some jurisdictions, treats a widely repeated short-shelf-life claim as a debunked myth, and records conflicting quantities and cadences alongside a separate nasal-spray form. Usernames are omitted and figures are logged as community provenance without endorsement. The planner above reproduces the arithmetic of these reported subcutaneous quantities; it does not validate them.
What remains uncertain
Which patients benefit, how schedules compare, long-term outcomes and applicability to unregulated vials remain uncertain.
Warnings and contraindications
Authorised indications and availability vary substantially by jurisdiction.
Schedules differ by disease, combination therapy and immune status.
Evidence from one infection or immune condition cannot support unrelated uses.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.